BeiGene to receive up to $1 billion in oncology deal with Novartis

Dow Jones2021-12-20

BeiGene Ltd. $(BGNE)$ said Monday it had entered an agreement with Swiss drug company Novartis Pharma AG (NOVN.EB) to develop its investigational TIGIT inhibitor ociperlimab in North America, Europe, and Japan and to market five Novartis oncology treatments in China. "Ociperlimab is an investigational potent TIGIT inhibitor with intact Fc function, believed to be critical for the anti-tumor activities of TIGIT antibodies," the companies said in a joint statement. Beijing-based BeiGene will receive an upfront payment of $300 million up to $700 million more on exercise by Novartis of a time-based option prior to mid-2023. After that it will be eligible for up to $745 million for reaching certain regulatory milestones, and $1.15 billion for sales milestones and royalties.

U.S.-listed shares of BeiGene were up 2.3% premarket.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

发表看法
1